MIRA Pharma to acquire SKNY in stock-for-stock deal; adds weight loss drug SKNY-1

MIRA PHARMACEUTICALS, INC.

SKNY contributes $5M in cash/assets at closing, no contingencies.
Exchange ratio determined by independent valuation; subject to SKNY valuation >= MIRA market value.
90-day mutual due diligence period; definitive agreement required within 180 days after.
No SKNY board, executives, or employees will retain roles post-closing.
SKNY stockholders subject to 6-month lock-up on MIRA shares received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.